KindlyMD, Inc. (NASDAQ:NAKA) Receives Average Rating of “Hold” from Analysts

Shares of KindlyMD, Inc. (NASDAQ:NAKA) have earned a consensus rating of “Hold” from the five analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $30.00.

A number of equities research analysts have commented on NAKA shares. TD Cowen started coverage on KindlyMD in a research report on Friday, April 10th. They set a “buy” rating and a $40.00 price objective for the company. Maxim Group decreased their price objective on KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Weiss Ratings upgraded KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen upgraded KindlyMD to a “sell” rating in a research report on Saturday, May 23rd.

Insider Buying and Selling at KindlyMD

In other news, CEO David F. Bailey purchased 55,115 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was bought at an average cost of $5.62 per share, with a total value of $309,746.30. Following the purchase, the chief executive officer directly owned 3,175,476 shares of the company’s stock, valued at approximately $17,846,175.12. This trade represents a 1.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders bought 191,448 shares of company stock worth $992,908. 24.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On KindlyMD

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of KindlyMD by 32,737.0% during the 3rd quarter. Vanguard Group Inc. now owns 6,036,750 shares of the company’s stock worth $150,557,000 after purchasing an additional 6,018,366 shares in the last quarter. Van ECK Associates Corp bought a new position in shares of KindlyMD in the 3rd quarter valued at approximately $111,339,000. Yorkville Advisors Global LP bought a new position in shares of KindlyMD in the 3rd quarter valued at approximately $231,942,000. RK Capital Management LLC FL bought a new position in shares of KindlyMD in the 3rd quarter valued at approximately $239,052,000. Finally, Stratos Wealth Partners LTD. bought a new position in shares of KindlyMD in the 4th quarter valued at approximately $1,571,000.

KindlyMD Stock Down 6.0%

NASDAQ:NAKA opened at $3.95 on Wednesday. KindlyMD has a 1-year low of $3.78 and a 1-year high of $659.20. The firm has a market capitalization of $68.73 million, a price-to-earnings ratio of -0.09 and a beta of 15.84. The stock has a fifty day simple moving average of $6.01 and a 200 day simple moving average of $10.32.

KindlyMD (NASDAQ:NAKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.38) EPS for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%.The business had revenue of $2.68 million for the quarter. Equities analysts predict that KindlyMD will post -16.8 earnings per share for the current year.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.